Skip to content
10-Q

Quarterly Report

TENAX THERAPEUTICS, INC. TENX

0001193125-26-219383

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 26.53M sh
Shares Diluted Q1 2026 · Mar 31, 2026 45.23M sh
Shares Diluted Q1 2026 · Mar 31, 2025 36.58M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$9.31M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$6.97M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $118.8M
Stockholders Equity Q1 2026 · Mar 31, 2026 $114.69M
Stockholders Equity Q1 2026 · Dec 31, 2025 $97.07M
Stockholders Equity Q1 2026 · Mar 31, 2025 $109.29M
Stockholders Equity Q1 2026 · Dec 31, 2024 $91.99M
Current Liabilities Q1 2026 · Mar 31, 2026 $8.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.16M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.49M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.16M
Current Assets Q1 2026 · Mar 31, 2026 $123.18M
Current Assets Q1 2026 · Dec 31, 2025 $104.23M
Total Assets Q1 2026 · Mar 31, 2026 $123.18M
Total Assets Q1 2026 · Dec 31, 2025 $104.23M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.35
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.28
Eps Basic Q1 2026 · Mar 31, 2026 −$0.35
Eps Basic Q1 2026 · Mar 31, 2025 −$0.28
Rd Expense Q1 2026 · Mar 31, 2026 $11.54M
Rd Expense Q1 2026 · Mar 31, 2025 $5.68M
Net Income Q1 2026 · Mar 31, 2026 −$15.72M
Net Income Q1 2026 · Mar 31, 2025 −$10.41M
Operating Income Q1 2026 · Mar 31, 2026 −$16.57M
Operating Income Q1 2026 · Mar 31, 2025 −$11.34M
Revenue Q1 2026 · Mar 31, 2026 $0